Accueil
Bioxera Pharma logo
Bioxera Pharma

Bioxera Pharma

1.5K
44
35
4.9(35)

À Propos de l'Entreprise

  • Raison sociale: Bioxera Pharma
  • Pays d'enregistrement: India
  • Adresse: Plot No. 10, Cama's Land, Municipal Industrial Estate,Goregaon East, Mumbai 400063
Description:

BioXera Pharma is a quality-focused manufacturer of APIs, veterinary APIs, and intermediates, with expertise in innovative process development for domestic and regulated international markets. The company operates a modern manufacturing facility in Ambernath, Maharashtra which has regulatory approvals like EU GMP, WHO GMP and has been audited by KFDA. Its flexible infrastructure supports development from laboratory scale to commercial production, enabling an expanding portfolio and pipeline. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

Activités Commerciales

Principes Actifs Pharmaceutiques (API)

Fabricant

Nos Produits & Services

Sell · Active Pharmaceutical Ingredients (APIs)
Pramoxine Hydrochloride
Sell · Active Pharmaceutical Ingredients (APIs)
Menbutone
Sell · Active Pharmaceutical Ingredients (APIs)
Ormeloxifene Hydrochloride
Sell · Active Pharmaceutical Ingredients (APIs)
Tropicamide
Sell · Active Pharmaceutical Ingredients (APIs)
Benfotiamine
Sell · Active Pharmaceutical Ingredients (APIs)
Bisbentiamine
Sell · Active Pharmaceutical Ingredients (APIs)
Amylmetacresol
Sell · Active Pharmaceutical Ingredients (APIs)
Eperisone Hydrochloride
Sell · Active Pharmaceutical Ingredients (APIs)
Benzydamine Hydrochloride
Sell · Active Pharmaceutical Ingredients (APIs)
Ethionamide
Sell · Active Pharmaceutical Ingredients (APIs)
Flavoxate
Sell · Active Pharmaceutical Ingredients (APIs)
Pitofenone Hydrochloride
Sell · Active Pharmaceutical Ingredients (APIs)
Prothionamide
Sell · Active Pharmaceutical Ingredients (APIs)
Doxylamine Succinate
Sell · Active Pharmaceutical Ingredients (APIs)
Metacresol

Certifications

Certificat CEP

Certificat WHO-GMP

GMP

Filtres :
Trier par :

    Aucun commentaire disponible.